Mark W. Bodmer
Chief Tech/Sci/R&D Officer chez EVELO BIOSCIENCES, INC.
Fortune : 1 158 $ au 31/03/2024
Profil
Mark W.
Bodmer is currently the Chief Scientific Officer and President-R&D at Evelo Biosciences, Inc. He previously held positions as the Chief Executive Officer at Biotica Technology Ltd.
and Hexagen Plc.
He was also the Chief Executive Officer at Lorantis Ltd.
from 1999 to 2004.
Additionally, he served as the Director at The Bioindustry Association from 2015 to 2016.
Dr. Bodmer has also worked as a Principal at The Wellcome Trust Ltd., UCB SA, Schroder Ventures Holdings Plc, Incyte Pharmaceuticals, Inc., Apax, and JPMorgan Partners Europe.
He obtained his undergraduate and doctorate degrees from the University of Cambridge.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EVELO BIOSCIENCES, INC.
0,14% | 08/11/2023 | 25 732 ( 0,14% ) | 1 158 $ | 31/03/2024 |
Postes actifs de Mark W. Bodmer
| Sociétés | Poste | Début |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 19/01/2016 |
Anciens postes connus de Mark W. Bodmer
| Sociétés | Poste | Fin |
|---|---|---|
| UCB | Corporate Officer/Principal | 01/04/2016 |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Director/Board Member | 01/04/2016 |
Lorantis Ltd.
 Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Lorantis Ltd. used to discover and develop drugs. The company had discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed. It used pursue immunology drug discovery and development programmes to address unmet medical needs. Lorantis was founded in 1998 and was headquartered in Cambridge, UK | President | 01/01/2004 |
Incyte Pharmaceuticals, Inc.
 Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Incyte Pharmaceuticals, Inc. engages in the provision of biopharmaceutical services. The company was founded in April, 1991 is headquartered in Palo Alto, CA. | Chief Tech/Sci/R&D Officer | 01/01/1999 |
Hexagen Plc
 Hexagen Plc BiotechnologyHealth Technology Part of Incyte Corp., Hexagen Plc develops technology for the discovery of single nucleotide polymorphisms. The British company was founded by Andrew Peter Sandham, Stephen William Bunting. Hexagen was acquired by Incyte Corp. on September 22, 1998 for $25.99 million. | Chief Executive Officer | - |
Formation de Mark W. Bodmer
| University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| UCB | Health Technology |
| EVELO BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
The Wellcome Trust Ltd.
 The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK. | Miscellaneous |
Biotica Technology Ltd.
 Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB. | Health Technology |
Schroder Ventures Holdings Plc
 Schroder Ventures Holdings Plc Financial ConglomeratesFinance Part of Schroders Plc, Schroder Ventures Holdings Plc is a private equity firm. | Finance |
Incyte Pharmaceuticals, Inc.
Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Incyte Pharmaceuticals, Inc. engages in the provision of biopharmaceutical services. The company was founded in April, 1991 is headquartered in Palo Alto, CA. | Health Technology |
Hexagen Plc
Hexagen Plc BiotechnologyHealth Technology Part of Incyte Corp., Hexagen Plc develops technology for the discovery of single nucleotide polymorphisms. The British company was founded by Andrew Peter Sandham, Stephen William Bunting. Hexagen was acquired by Incyte Corp. on September 22, 1998 for $25.99 million. | Health Technology |
Lorantis Ltd.
Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Lorantis Ltd. used to discover and develop drugs. The company had discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed. It used pursue immunology drug discovery and development programmes to address unmet medical needs. Lorantis was founded in 1998 and was headquartered in Cambridge, UK | Health Technology |
| Apax | Consumer Durables |
JPMorgan Partners Europe
 JPMorgan Partners Europe Financial ConglomeratesFinance Part of JPMorgan Chase & Co., JPMorgan Partners Europe is a private equity group. The private company is based in London, UK. | Finance |
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Commercial Services |
